Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 13/20 | 0.59 |
| ▸ | PARP1 | P09874 | 6/20 | 0.56 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.56 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11794359 | 0.80 | HCAR2 (0.61) | HCAR2PARP1 | |
| SCHEMBL26017631 | 0.79 | HCAR2 (0.59) | HCAR2PARP1 | |
| SCHEMBL20954965 | 0.79 | HCAR2 (0.59) | HCAR2PARP1 | |
| SCHEMBL11781060 | 0.79 | HCAR2 (0.59) | HCAR2PARP1 | |
| SCHEMBL10984818 | 0.79 | HCAR2 (0.59) | HCAR2PARP1 | |
| SCHEMBL11578825 | 0.78 | HCAR2 (0.62) | HCAR2TNKS2 | |
| SCHEMBL14820137 | 0.78 | HCAR2 (0.55) | HCAR2PARP1 | |
| SCHEMBL15775973 | 0.78 | TNKS (0.62) | HCAR2PARP1TNKS2 | |
| SCHEMBL11667578 | 0.76 | HCAR2 (0.56) | HCAR2PARP1KDM4E | |
| SCHEMBL21072770 | 0.75 | HCAR2 (0.62) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9475822-B2 | Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9475822-B2 | Substituted 2- amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-25 | — | — | US | disclosed |
| US-9212149-B2 | Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212149-B2 | Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150329556-A1 | SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-11-19 | — | — | US | disclosed |
| US-20150329556-A1 | SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-1740551-B9 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-1740551-B1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| WO-2007002701-A2 | ANTI-INFLAMMATORY ARYL NITRILE COMPOUNDS | AMGEN INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060270849-A1 | Process for producing pyrimidin-4-one compound | UBE INDUSTRIES, LTD. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1637523-A1 | PROCESS FOR PRODUCING PYRIMIDIN-4-ONE COMPOUND | Ube Industries, Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005105760-A1 | HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF AS AN MMP-13 INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | WO | disclosed |
| US-4134981-A | ANTIALLERGENS | PFIZER INC. (US) | 1979-01-16 | — | — | US | disclosed |
| US-4120962-A | Fused pyrimidin-4(3H)-ones as antiallergy agents | PFIZER INC. (US) | 1978-10-17 | — | — | US | disclosed |
| US-4044134-A | FUSED WITH QUINOLINE OR PYRIDINE, 2-METHYL, ETHYL, OR ACETYL GROUP | PFIZER INC. (US) | 1977-08-23 | — | — | US | disclosed |
| US-3974161-A | Fused pyrimidin-4(3H)-ones as antiallergy agents | PFIZER INC. (US) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329556-A1 | SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS | MMP13, MMP14, MMP25 | HCAR2 68/4885PARP1 1005/4885TNKS2 2587/4885 |
| US-20080027050-A1 | Heterocyclic Amide Compound and Use Thereof as an Mmp-13 Inhibitor(Amended Ex Officio) | MMP13, HDAC11, HDAC1 | HCAR2 133/4885PARP1 1490/4885TNKS2 4714/4885 |
| US-20060270849-A1 | Process for producing pyrimidin-4-one compound | DDC, ODC1, APRT | HCAR2 1690/4885PARP1 445/4885TNKS2 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.